First study niraparib

Author: swoc

August undefined, 2024

WebSep 3, 2024 · Niraparib is an oral, selective PARP-1/2 inhibitor approved for the treatment of advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. … WebFeb 18, 2024 · “The MAGNITUDE study results support niraparib plus abiraterone as a new first-line treatment option for patients with mCRPC and alterations in genes associated with HRR,” lead study author Kim N. Chi, MD, senior research scientist, Vancouver Prostate Centre, chief medical officer and vice president, BC Cancer, medical oncologist, BC …

Zai Lab Presents Positive Results from Phase 3 PRIME Study

WebApr 11, 2024 · At the beginning of the study period, due to economic reasons, niraparib was often reserved as a last resort when patients were resistant or intolerable to … WebNiraparib is also in development for use in other solid tumours, including breast and prostate cancer. This article summarizes the milestones in the development of niraparib … c sharp text

PRIMA study: Niraparib maintenance improves PFS in advanced OC

WebApr 12, 2024 · The investigational PARP inhibitor senaparib (JS109/IMP4297) was found to prolong progression-free survival (PFS) in patients with advanced ovarian cancer, meeting the primary end point of the phase 3 FLAMES study (NCT04169997). 1. Senaparib was designed to selectively bind to PARP 1/2 and prevent PARP-mediated repair of single … WebMar 22, 2024 · The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVARIO study presented by Melissa M. Hardesty, MD, MPH, during the Society of Gynecologic Oncology (SGO) 2024 Virtual … WebFeb 17, 2024 · Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology … c sharp textwriter

Niraparib Plus Bevacizumab Shows Clinical Benefit in Patients …

Overview Niraparib for maintenance treatment of advanced …

WebMar 1, 2024 · The NDA is supported by data from the MAGNITUDE study (NCT03748641), a Phase 3, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of niraparib plus AAP as a first-line treatment in patients with mCRPC, with or without alterations in HRR associated genes. 1 Patients with HRR gene … WebApr 14, 2024 · A study of ovarian cancers found that the loss of TP53, a tumour suppressor gene which has direct and indirect roles within the DDR ... assessed the safety and efficacy of combination niraparib and bevacizumab as first-line maintenance for newly diagnosed advanced-stage ovarian cancer. Analysis at 28.7 months found a median PFS of 28.3 … c sharp the questWebJul 7, 2024 · Despite a very small sample size, it is notable that the median progression-free survival in niraparib plus nivolumab was similar to the placebo group of the POLO study (3·8 months), whereas the median progression-free survival of 10·4 months in the niraparib plus ipilimumab group was closer to that shown in the experimental group of the POLO ... csharp testing framework

"WebMar 22, 2024 · In this review, we will first summarize the clinical outcomes of the four FDA-approved PARPi in treating BRCA1/2 deficient cancers. ... The FDA then expedited the approval of rucaparib and niraparib based on the ARIEL2 and Study 10 clinical trials for rucaparib and the QUADRA clinical trial for niraparib (Oza et al., 2024; ... " - First study niraparib

First study niraparib

JASPER: Phase 2 trial of first-line niraparib plus ... - PubMed

WebMar 21, 2024 · The PRIMA study previously conducted by Zai Lab’s partner GlaxoSmithKline plc (GSK) demonstrated that niraparib conferred a PFS benefit to … WebJul 2, 2024 · Study Description Go to Brief Summary: This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described …

Did you know?

Web• Conduct clinical data review on Medidata Rave ® for the FIRST study (dostarlimab and niraparib as First-line Treatment of Stage III or IV … WebOct 29, 2024 · European Commission approves Zejula (niraparib) as first-line monotherapy maintenance treatment in advanced ovarian cancer . For media and investors only. ...

WebTime to First Subsequent Therapy (TFST) and Progression-Free Survival 2 (PFS2) From the Phase 3 Randomized, Double-Blind PRIMA/ENGOT-V26/GOG-3012 Study in Patients With Newly Diagnosed Ovarian Cancer ... • Niraparib significantly improved PFS in patients with HRd tumors and in the overall population 1L, first-line; CI, confidence interval; CT ... WebNiraparib is marketed in the United States and Europe under the trade name Zejula ®. About PRIMA. PRIMA is a double-blind, randomised Phase 3 study designed to evaluate niraparib versus placebo in first-line Stage III or IV ovarian cancer patients.

Web1 day ago · Niraparib, or the MAGNITUDE trial, looked at patients with metastatic CRPC for first-line therapy randomized to either ARPI or abiraterone versus abiraterone plus niraparib. Now, what's different of the MAGNITUDE study compared to the other two that have been recently reported now is that it had a prospective selection of the patients ... WebThe study was conducted in accordance with the eth-ical standards of the Declaration of Helsinki, and the ... ZEJULAR (Niraparib) for First-Line Maintenance Treat-mentofOvarianCancerinChina[Internet].GlobeNewswire News Room. 2024 [cited 2024 May 17]. Available from:

WebApr 11, 2024 · Of the total 142 patients, 93 received niraparib as first-line maintenance therapy, 31 as maintenance therapy for platinum-sensitive recurrent ovarian cancer, and 18 as salvage treatment. ... The study was conducted in accordance with the ethical standards of the Declaration of Helsinki, and the ethics committee of the main study center Fudan ...

WebFeb 16, 2024 · Chi et al. Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. ASCO GU 2024. csharp tftp serverWebSep 3, 2024 · The primary strength of this study is that it represents one of the first investigations of a PARP inhibitor with a PD-1 inhibitor for the first-line treatment of NSCLC. Niraparib in combination with pembrolizumab … csharp textwriterWebPRIMA is a double-blind, randomised Phase 3 study designed to evaluate niraparib versus placebo in first-line Stage III or IV ovarian cancer patients. The study assessed the … ea form hilangWebSep 6, 2024 · The study had a single arm: All participants were prescribed niraparib 300 mg per day, which was given as oral capsules. In order to assess the effectiveness of … csharp thisWebJan 1, 2024 · This study f … The JASPER clinical trial studied a new combination treatment for advanced or metastatic non-small cell lung cancer (NSCLC). ... ≥50% (cohort 1) or 1%-49% (cohort 2) received first-line niraparib (200 mg once daily) plus pembrolizumab (200 mg every 3 weeks). The primary end point was investigator-assessed objective response ... ea form lhdn 2022WebNov 30, 2024 · A study of niraparib combined with MGD013 in patients with advanced or metastatic solid tumor who failed prior treatment. clinicaltrials.gov. Updated April 1, 2024. Accessed November 30, 2024 ... csharp this parameterWebOct 29, 2024 · European Commission approves Zejula (niraparib) as first-line monotherapy maintenance treatment in advanced ovarian cancer . For media and investors only. ... The study was later amended to incorporate an individualised starting dose of either 200 mg or 300 mg of Zejula once-daily based on the patient’s baseline … c sharp this